Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IDEAYA Biosciences, Inc.IDYA · Entity 4069 | SVP, Head of Biology | February 24, 2021 | February 27, 2021 |
| Zentalis Pharmaceuticals, Inc.ZNTL · Entity 5772 | Chief Scientific Officer | February 03, 2025 | February 05, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IDEAYA Biosciences, Inc.
Report date February 24, 2021 · Filed February 27, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.52 · Expires 2031-02-23 | Direct | 45,000 |
Reported balance
After 2021-02-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-02-24 · Grant · Acquired 45,000 · Balance 45,000 F1: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2021 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2021 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
Zentalis Pharmaceuticals, Inc.
Report date February 03, 2025 · Filed February 05, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 512,856 |
Ending reported balance
After 2025-02-03 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-02-03 · Grant · Acquired 335,907 · Balance 527,224 F1: Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a two year period following the grant date, subject to the Reporting Person's continued service with the Issuer. Row 2 · 2025-02-03 · Sale · Disposed 14,368 · Balance 512,856 F2: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.68 · Expires 2035-02-02 | Direct | 124,714 |
Reported balance
After 2025-02-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-02-03 · Grant · Acquired 124,714 · Balance 124,714 F3: The options will vest over four years in substantially equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a two year period following the grant date, subject to the Reporting Person's continued service with the Issuer.
F2: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person.
F3: The options will vest over four years in substantially equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 03, 2025 Filed Feb 5, 2025 23:32 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantStock Option (Right to Buy) · Derivative | 124,714 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001725160-25-000041 · wk-form4_1738798344.xml · derivative · entry 3 Lackner Mark · CIK 0001777413 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,714 Underlying: Common Stock · 124,714 shares Expires 2035-02-02 F3 · derivative.exercise_date: The options will vest over four years in substantially equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 23:32 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 14,368 | $1.71 | $24,590.83 |
DisclosureSEC source: 0001725160-25-000041 · wk-form4_1738798344.xml · nonDerivative · entry 2 Lackner Mark · CIK 0001777413 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 512,856 F2 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 23:32 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantCommon Stock | 335,907 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-25-000041 · wk-form4_1738798344.xml · nonDerivative · entry 1 Lackner Mark · CIK 0001777413 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 527,224 F1 · shares: Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a two year period following the grant date, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 22:17 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 4,411 | $3.12 | $13,762.32 |
DisclosureSEC source: 0001725160-25-000002 · wk-form4_1735942617.xml · nonDerivative · entry 1 Lackner Mark · CIK 0001777413 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 191,317 F1 · kind: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. Read SEC document |
| February 02, 2024 Filed Feb 6, 2024 00:15 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,585 | $11.54 | $18,290.90 |
DisclosureSEC source: 0001725160-24-000034 · wk-form4_1707178516.xml · nonDerivative · entry 2 Lackner Mark · CIK 0001777413 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 195,728 F2 · kind: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $11.35 to $11.64. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 01, 2024 Filed Feb 6, 2024 00:15 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantStock Option (Right to Buy) · Derivative | 141,000 | $0.00 Strike: $11.69 | $0.00 |
DisclosureSEC source: 0001725160-24-000034 · wk-form4_1707178516.xml · derivative · entry 3 Lackner Mark · CIK 0001777413 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 141,000 Underlying: Common Stock · 141,000 shares Expires 2034-01-31 F4 · derivative.exercise_date: The options will vest over four years in equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer. The options are Reporting Person's annual equity grants, which reflect the market data for Reporting Person's role as Chief Scientific Officer, a role to which he was promoted on December 31, 2023. Read SEC document |
| February 01, 2024 Filed Feb 6, 2024 00:15 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantCommon Stock | 141,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-24-000034 · wk-form4_1707178516.xml · nonDerivative · entry 1 Lackner Mark · CIK 0001777413 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 197,313 F1 · shares: Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 01:21 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $15.99 | $0.00 |
DisclosureSEC source: 0001725160-24-000004 · wk-form4_1704331256.xml · derivative · entry 2 Lackner Mark · CIK 0001777413 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2034-01-02 F2 · derivative.exercise_date: The options were granted to the Reporting Person in connection with Reporting Person's previously disclosed promotion to Chief Scientific Officer, which became effective December 31, 2023. The options will vest over four years in equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 01:21 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-24-000004 · wk-form4_1704331256.xml · nonDerivative · entry 1 Lackner Mark · CIK 0001777413 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,313 F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person in connection with Reporting Person's previously disclosed promotion to Chief Scientific Officer, which became effective December 31, 2023. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in substantially equal annual installments on the first, second, third and fourth anniversaries of the vesting commencement date of December 31, 2023, subject to the Reporting Person's continuing service with the Issuer. Read SEC document |
| February 24, 2021 Filed Feb 27, 2021 00:10 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $19.52 | $0.00 |
DisclosureSEC source: 0001567619-21-005114 · doc1.xml · derivative · entry 1 Lackner Mark · CIK 0001777413 · SVP, Head of Biology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2031-02-23 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2021 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| February 10, 2021 Filed Feb 10, 2021 23:53 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionStock Option (right to buy) · Derivative | 596 | $0.00 Strike: $6.98 | $0.00 |
DisclosureSEC source: 0001567619-21-002852 · doc1.xml · derivative · entry 10 Lackner Mark · CIK 0001777413 · SVP, Head of Biology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,014 Underlying: Common Stock · 596 shares Expires 2028-12-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from December 11, 2018 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| February 10, 2021 Filed Feb 10, 2021 23:53 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 596 | $21.00 | $12,516.00 |
DisclosureSEC source: 0001567619-21-002852 · doc1.xml · nonDerivative · entry 7 Lackner Mark · CIK 0001777413 · SVP, Head of Biology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| February 10, 2021 Filed Feb 10, 2021 23:53 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionCommon Stock | 596 | $6.98 | $4,160.08 |
DisclosureSEC source: 0001567619-21-002852 · doc1.xml · nonDerivative · entry 6 Lackner Mark · CIK 0001777413 · SVP, Head of Biology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 596 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2021 Filed Feb 10, 2021 23:53 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionStock Option (right to buy) · Derivative | 1,104 | $0.00 Strike: $6.98 | $0.00 |
DisclosureSEC source: 0001567619-21-002852 · doc1.xml · derivative · entry 9 Lackner Mark · CIK 0001777413 · SVP, Head of Biology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,610 Underlying: Common Stock · 1,104 shares Expires 2028-12-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from December 11, 2018 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| February 09, 2021 Filed Feb 10, 2021 23:53 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 1,104 | $21.05 | $23,234.34 |
DisclosureSEC source: 0001567619-21-002852 · doc1.xml · nonDerivative · entry 5 Lackner Mark · CIK 0001777413 · SVP, Head of Biology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades in prices ranging from $21.00 to $21.11, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| February 09, 2021 Filed Feb 10, 2021 23:53 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionCommon Stock | 1,104 | $6.98 | $7,705.92 |
DisclosureSEC source: 0001567619-21-002852 · doc1.xml · nonDerivative · entry 4 Lackner Mark · CIK 0001777413 · SVP, Head of Biology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,104 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 23:53 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionStock Option (right to buy) · Derivative | 300 | $0.00 Strike: $6.98 | $0.00 |
DisclosureSEC source: 0001567619-21-002852 · doc1.xml · derivative · entry 8 Lackner Mark · CIK 0001777413 · SVP, Head of Biology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,714 Underlying: Common Stock · 300 shares Expires 2028-12-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from December 11, 2018 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 23:53 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 200 | $21.00 | $4,200.00 |
DisclosureSEC source: 0001567619-21-002852 · doc1.xml · nonDerivative · entry 3 Lackner Mark · CIK 0001777413 · SVP, Head of Biology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 23:53 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 100 | $21.02 | $2,102.00 |
DisclosureSEC source: 0001567619-21-002852 · doc1.xml · nonDerivative · entry 2 Lackner Mark · CIK 0001777413 · SVP, Head of Biology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 23:53 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionCommon Stock | 300 | $6.98 | $2,094.00 |
DisclosureSEC source: 0001567619-21-002852 · doc1.xml · nonDerivative · entry 1 Lackner Mark · CIK 0001777413 · SVP, Head of Biology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 21:59 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionStock Option (right to buy) · Derivative | 1,123 | $0.00 Strike: $6.98 | $0.00 |
DisclosureSEC source: 0001567619-21-001669 · doc1.xml · derivative · entry 6 Lackner Mark · CIK 0001777413 · SVP, Head of Biology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,014 Underlying: Common Stock · 1,123 shares Expires 2028-12-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from December 11, 2018 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 21:59 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionStock Option (right to buy) · Derivative | 377 | $0.00 Strike: $4.62 | $0.00 |
DisclosureSEC source: 0001567619-21-001669 · doc1.xml · derivative · entry 5 Lackner Mark · CIK 0001777413 · SVP, Head of Biology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,760 Underlying: Common Stock · 377 shares Expires 2028-06-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from May 31, 2018 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 21:59 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 800 | $18.79 | $15,033.52 |
DisclosureSEC source: 0001567619-21-001669 · doc1.xml · nonDerivative · entry 4 Lackner Mark · CIK 0001777413 · SVP, Head of Biology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades in prices ranging from $18.68 to $18.895, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 21:59 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 1,701 | $18.30 | $31,124.39 |
DisclosureSEC source: 0001567619-21-001669 · doc1.xml · nonDerivative · entry 3 Lackner Mark · CIK 0001777413 · SVP, Head of Biology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800 F2 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades in prices ranging from $17.68 to $18.62, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 21:59 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionCommon Stock | 1,123 | $6.98 | $7,838.54 |
DisclosureSEC source: 0001567619-21-001669 · doc1.xml · nonDerivative · entry 2 Lackner Mark · CIK 0001777413 · SVP, Head of Biology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,501 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 21:59 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionCommon Stock | 377 | $4.62 | $1,741.74 |
DisclosureSEC source: 0001567619-21-001669 · doc1.xml · nonDerivative · entry 1 Lackner Mark · CIK 0001777413 · SVP, Head of Biology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,378 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,001 shares acquired pursuant to Issuer's Employee Stock Purchase Plan on November 30, 2020. Read SEC document |
| June 17, 2020 Filed Jun 18, 2020 22:03 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionStock Option (right to buy) · Derivative | 373 | $0.00 Strike: $4.62 | $0.00 |
DisclosureSEC source: 0001567619-20-012387 · doc1.xml · derivative · entry 8 Lackner Mark · CIK 0001777413 · SVP, Head of Biology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,137 Underlying: Common Stock · 373 shares Expires 2028-06-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from May 31, 2018 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| June 17, 2020 Filed Jun 18, 2020 22:03 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 373 | $19.91 | $7,427.74 |
DisclosureSEC source: 0001567619-20-012387 · doc1.xml · nonDerivative · entry 5 Lackner Mark · CIK 0001777413 · SVP, Head of Biology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F5 · price: This transaction was executed in multiple trades in prices ranging from $19.84 to $19.97, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| June 17, 2020 Filed Jun 18, 2020 22:03 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionCommon Stock | 373 | $4.62 | $1,723.26 |
DisclosureSEC source: 0001567619-20-012387 · doc1.xml · nonDerivative · entry 4 Lackner Mark · CIK 0001777413 · SVP, Head of Biology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 373 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 22:03 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionStock Option (right to buy) · Derivative | 2,863 | $0.00 Strike: $6.98 | $0.00 |
DisclosureSEC source: 0001567619-20-012387 · doc1.xml · derivative · entry 7 Lackner Mark · CIK 0001777413 · SVP, Head of Biology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,137 Underlying: Common Stock · 2,863 shares Expires 2028-12-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from December 11, 2018 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 22:03 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionStock Option (right to buy) · Derivative | 3,887 | $0.00 Strike: $4.62 | $0.00 |
DisclosureSEC source: 0001567619-20-012387 · doc1.xml · derivative · entry 6 Lackner Mark · CIK 0001777413 · SVP, Head of Biology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,510 Underlying: Common Stock · 3,887 shares Expires 2028-06-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from May 31, 2018 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 22:03 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 6,750 | $14.93 | $100,760.63 |
DisclosureSEC source: 0001567619-20-012387 · doc1.xml · nonDerivative · entry 3 Lackner Mark · CIK 0001777413 · SVP, Head of Biology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades in prices ranging from $14.84 to $15.10, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 22:03 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionCommon Stock | 2,863 | $6.98 | $19,983.74 |
DisclosureSEC source: 0001567619-20-012387 · doc1.xml · nonDerivative · entry 2 Lackner Mark · CIK 0001777413 · SVP, Head of Biology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 22:03 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionCommon Stock | 3,887 | $4.62 | $17,957.94 |
DisclosureSEC source: 0001567619-20-012387 · doc1.xml · nonDerivative · entry 1 Lackner Mark · CIK 0001777413 · SVP, Head of Biology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,887 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 21:40 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 104 | $10.11 | $1,050.96 |
DisclosureSEC source: 0001567619-20-011730 · doc1.xml · nonDerivative · entry 3 Lackner Mark · CIK 0001777413 · SVP, Head of Biology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F5 · price: This transaction was executed in multiple trades in prices ranging from $10.09 to $10.19, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 845 shares acquired pursuant to Issuer's Employee Stock Purchase Plan on May 29, 2020. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 21:40 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 333 | $9.73 | $3,240.79 |
DisclosureSEC source: 0001567619-20-011730 · doc1.xml · nonDerivative · entry 2 Lackner Mark · CIK 0001777413 · SVP, Head of Biology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades in prices ranging from $9.09 to $10.07, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 845 shares acquired pursuant to Issuer's Employee Stock Purchase Plan on May 29, 2020. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 21:40 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 408 | $8.55 | $3,487.38 |
DisclosureSEC source: 0001567619-20-011730 · doc1.xml · nonDerivative · entry 1 Lackner Mark · CIK 0001777413 · SVP, Head of Biology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 437 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades in prices ranging from $8.05 to $9.00, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 845 shares acquired pursuant to Issuer's Employee Stock Purchase Plan on May 29, 2020. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 21:03 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $6.92 | $0.00 |
DisclosureSEC source: 0001567619-20-004803 · doc1.xml · derivative · entry 1 Lackner Mark · CIK 0001777413 · SVP, Head of Biology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2030-02-20 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2020 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.